Compare Johnson & Johnson (JNJ) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Palantir Technologies Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Palantir Technologies Inc trades at $208.09 (market cap $477.68B). The key difference: Johnson & Johnson is the larger of the two by market cap, and Johnson & Johnson pays a 2.09% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Palantir Technologies Inc for 78 Days on average.
| JNJ | PLTR | |
|---|---|---|
Market Cap | $618.09B | $477.68B |
Volume | 6,050,983 | 41,744,992 |
Sector | Health | Technology |
52-Week High | $278.43 | $207.18 |
52-Week Low | $186.00 | $107.27 |
Typical Hold Time | 129 Days | 78 Days |
Enterprise Value | $646.37B | $468.48B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Palantir (PLTR) trades at $209.05, up 7.74% with strong bullish momentum as it approaches resistance at $209. The stock shows exceptional fundamental performance with 56.2% revenue growth in 2025, net income margin expanding to 36.3%, and consistent earnings beats. Recent partnership with Armada for sovereign AI infrastructure and positive analyst coverage support the upward trend, though valuation metrics remain elevated with P/E of 169.9 and P/S of 83.02.
Outlook remains positive given accelerating AI adoption and strong commercial growth (149% YoY US commercial revenue). Key risks include premium valuation sensitivity and competitive AI market pressures. Analyst consensus at $191.69 suggests potential near-term consolidation, but continued execution could justify higher multiples. Cash flow trends show strong operational performance despite significant investing outlays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
